|Description||KML-29, a effective MAGL inhibitor, has been found to have probable effect against neuropathic pain. IC50: 15, 43, and 5.9 nM (mouse, rat, and human brain proteomes).|
|Synonyms||KML-29; KML29; KML 29; SCHEMBL15100615; SXHQLPHDBLTFPM-UHFFFAOYSA-N; BDBM179929; IN2183; ZINC97949367|
|Solubility||10 mM in DMSO|
|Application||KML-29 is a effective MAGL inhibitor that has been found to have probable effect against neuropathic pain.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
JJKK 048, a benzodioxol derivative, has been found to a MAGL inhibitor that could probably be significant in anticancer and anti-inflammatory studies. IC50: 0.4...
MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor that modulates the synaptic processes. MJN110 has the potential for the treatment of a...
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic p...
NF 1819 is a selective irreversible β-lactam-based monoacylglycerol lipase inhibitor with IC50 values of 0.25 and 7.4 nM at rMAGL and hMAGL.
SAR-629 is a Monoglyceride lipase (MGL) inhibitor and can also be known as 2-arachidonoylglycerol (2-AG) degradation inhibitor. MGL is a serine hydrolase which ...
KML-29, a effective MAGL inhibitor, has been found to have probable effect against neuropathic pain. IC50: 15, 43, and 5.9 nM (mouse, rat, and human brain prote...
JZL 184 is the first selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 nM.
JZP 361 is a reversible, potent and selective inhibitor of human recombinant MAGL (hMAGL) with IC50 value of 46 nM. It shows affinity for H1 receptors but shows...